Fosaprepitant

Fosaprepitant
Clinical data
[[Regulation of therapeutic goods \|Template:Engvar data]]	EU EMA: by INN; US FDA: Fosaprepitant;
Pregnancy; category	US: B (No risk in non-human studies) ; ;
Routes of; administration	Intravenous
ATC code	A04AD12 (WHO) ;
Legal status
Legal status	US: ℞-only ;
Pharmacokinetic data
Bioavailability	n/a
Protein binding	>95% (aprepitant)
Metabolism	To aprepitant
Elimination half-life	9 to 13 hours (aprepitant)
Identifiers
	IUPAC name [3-{[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl] ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl}-5-oxo- 2H-1,2,4-triazol-1-yl]phosphonic acid;
CAS Number	172673-20-0 265121-04-8 (dimeglumine);
PubChem CID	219090;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C23H22F7N4O6P
Molar mass	614.406 g/mol

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Fosaprepitant (INN; trade names Emend for Injection, Ivemend) is an anti-emetic drug, administered intravenously. It is a prodrug of aprepitant.

It was developed by Merck & Co. and was approved by the United States Food and Drug Administration (FDA) on January 25, 2008 .^[1] and by the European Medicines Agency (EMA) on January 11 of the same year.^[2]

References

↑ "Drugs.com, FDA Approves Emend (fosaprepitant dimeglumine) for Injection, Merck's New Intravenous Therapy, for Use in Combination with Other Antiemetics for Prevention of Nausea and Vomiting Caused by Chemotherapy". Retrieved 2008-03-15.
↑ "European Public Assessment Report for Ivemend (from the EMEA website)". Retrieved 2008-03-15.

Template:Antiemetics and antinauseants

Template:WikiDoc Sources Template:Jb1

[1] "Drugs.com, FDA Approves Emend (fosaprepitant dimeglumine) for Injection, Merck's New Intravenous Therapy, for Use in Combination with Other Antiemetics for Prevention of Nausea and Vomiting Caused by Chemotherapy". Retrieved 2008-03-15.

[2] "European Public Assessment Report for Ivemend (from the EMEA website)". Retrieved 2008-03-15.

[1]

[2]

v t e Merck & Co., Inc.
Corporate Directors:	Richard Clark · Johnnetta Cole · William Harrison · William Kelley · Rochelle Lazarus · Thomas Shenk · Anne Tatlock · Samuel Thier · Wendell Weeks · Peter Wendell
Products:	Indinavir · Aprepitant · Alendronate · Rizatriptan · Finasteride · Losartan · Lovastatin · Montelukast · Rofecoxib · Ezetimibe/simvastatin · Ezetimibe · Raltegravir · Simvastatin · Sitagliptin · Vorinostat · The Merck Index · The Merck Manual
Annual Revenue: $22.9 billion USD (profit 2% Fiscal year 2004) · Employees: 63,000 · Stock Symbol: MRK · Website: www.merck.com

Clinical data

[[Regulation of therapeutic goods \|Template:Engvar data]]	EU EMA: by INN US FDA: Fosaprepitant
Pregnancy category	US: B (No risk in non-human studies)
Routes of administration	Intravenous
ATC code	A04AD12 (WHO)
Legal status
Legal status	US: ℞-only
Pharmacokinetic data
Bioavailability	n/a
Protein binding	>95% (aprepitant)
Metabolism	To aprepitant
Elimination half-life	9 to 13 hours (aprepitant)
Identifiers
IUPAC name [3-{[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl] ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl}-5-oxo- 2H-1,2,4-triazol-1-yl]phosphonic acid
CAS Number	172673-20-0 265121-04-8 (dimeglumine)
PubChem CID	219090
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C₂₃H₂₂F₇N₄O₆P
Molar mass	614.406 g/mol

Fosaprepitant

References

Navigation menu

Search